## **Armando Magrelli Curriculum Vitae**

- Name: Armando Magrelli
- Date of Birth: January 21, 1964
- Nationality: Italian
- Email: armando.magrelli@iss.it
- Work Address: National Center for Drug Research and Evaluation, ISTITUTO SUPERIORE DI SANITÀ, Viale Regina Elena, 299, 00161, Rome, Italy

## **Professional Experience**

- Vice Chair, Committee for Orphan Medicinal Products, European Medicines Agency (EMA), from October 1, 2018.
- European Commission Representative at the Committee for Orphan Medicinal Products, EMA, since May 20, 2021.
- Expert, Commission for the Evaluation of Eligibility for Phase I Clinical Trials, ISTITUTO SUPERIORE DI SANITÀ, since November 13, 2020.
- Expert on the European Commission for the Evaluation of Research Projects, since January 2, 2020.
- Contract Professor, University of Rome "Tor Vergata," teaching "European Pharmaceutical Legislation" since October 1, 2017.
- Member, Scientific Advice Working Party, EMA, since March 1, 2013.

### Education

- M.Sc. in Biology, University of Rome La Sapienza, 1988-1992.
- Post-Doctoral Fellow, Max-Planck-Institute for Plant Breeding Research, 1993-1997.

#### Skills and Certifications

- Languages: Italian (native), English (advanced).
- Technical Skills: Extensive experience with operating systems, programming, and web development tools.

### **Publications**

• Contributed to numerous scientific publications in the fields of rare diseases, orphan drugs, and regulatory frameworks.

# **Professional Memberships**

• Registered with the National Professional Association of Biologists since June 7, 1996.

Armando Magrelli's extensive experience in pharmaceutical regulation, clinical trial evaluation, and academic teaching, emphasizing his role in orphan drug assessment and his contributions to European health policy.

Armando Magrelli's research experience is highlighted through his various roles and contributions in the field of medical research, particularly focused on rare diseases and pharmacology. Here are the key points from his CV:

- 1. First Researcher at the Istituto Superiore di Sanità (Since July 1, 2008): Engaged in multiple research projects on the role of microRNAs in rare diseases, epidemiology of rare diseases, hepatoblastoma, multiple exostoses, Hailey-Hailey disease, and bioinformatics.
- 2. Evaluation of Clinical and Non-Clinical Aspects of Medicinal Products: Responsible for the evaluation of clinical and non-clinical documentation for the authorization of human medicinal products, both at the national and centralized European level.
- 3. Member of the Scientific Advice Working Party at the EMA: Coordinated over 140 centralized European procedures for scientific advice on human medicines as an Italian delegate.
- 4. Bioinformatician at the Rome Oncogenomic Center IFO: Focused on functional oncogenomics for the diagnosis and treatment of human tumors, and developed bioinformatics software available to the scientific community.
- 5. Researcher at the National Research Council (CNR): Developed a new mouse model demonstrating RNA interference phenomena in higher organisms.
- 6. Senior Researcher at IDI Pharmaceuticals: Set up a molecular biology lab and conducted advanced genetic and cell culture work to produce functional human skin for grafting.
- 7. Bioinformatics and Data Analysis Consultant at the University of Rome "La Sapienza": Developed new bioinformatics approaches for the study of microRNAs and their targets.
- 8. Participation in International Projects and Grants:
  - SIROCCO Project: Funded by the European Commission, focusing on RNA silencing mechanisms.
  - o TEDDY Network: European project for drug development for the young.
  - o Rare 2030 Project: A foresight study, co-funded by the EU, looking into policy frameworks supporting rare disease patients.
  - o GetReal Initiative: Involvement in real-world evidence methodologies.

These roles underscore Magrelli's extensive background in scientific research, particularly in genetic research, pharmacology, and innovative treatments for rare conditions, with significant contributions to international projects and collaborations.